Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.16 Insider Own10.10% Shs Outstand27.03M Perf Week-7.07%
Market Cap92.44M Forward P/E- EPS next Y-2.10 Insider Trans0.00% Shs Float24.30M Perf Month-24.84%
Income-29.36M PEG- EPS next Q-0.41 Inst Own54.15% Short Float4.13% Perf Quarter-15.76%
Sales1.06M P/S87.21 EPS this Y-43.42% Inst Trans-91.35% Short Ratio4.93 Perf Half Y-31.05%
Book/sh4.23 P/B0.81 EPS next Y3.44% ROA-40.57% Short Interest1.00M Perf Year64.42%
Cash/sh4.41 P/C0.78 EPS next 5Y- ROE-46.47% 52W Range1.62 - 24.71 Perf YTD-33.46%
Dividend Est.- P/FCF- EPS past 5Y43.79% ROI-25.34% 52W High-86.16% Beta0.75
Dividend TTM- Quick Ratio23.54 Sales past 5Y89.88% Gross Margin27.63% 52W Low111.11% ATR (14)0.20
Dividend Ex-Date- Current Ratio23.54 EPS Y/Y TTM74.68% Oper. Margin-3103.48% RSI (14)22.19 Volatility5.91% 4.57%
Employees39 Debt/Eq0.02 Sales Y/Y TTM-133.77% Profit Margin-2759.59% Recom1.00 Target Price13.50
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q79.36% Payout- Rel Volume0.76 Prev Close3.52
Sales Surprise-52.18% EPS Surprise182.76% Sales Q/Q12.36% EarningsJun 11 AMC Avg Volume203.59K Price3.42
SMA20-13.49% SMA50-22.72% SMA200-24.13% Trades Volume154,706 Change-2.84%
Date Action Analyst Rating Change Price Target Change
Dec-07-23Upgrade Jefferies Hold → Buy $15
Aug-07-23Upgrade Maxim Group Hold → Buy $30
Jul-22-22Downgrade William Blair Outperform → Mkt Perform
Jul-22-22Downgrade Robert W. Baird Outperform → Neutral
Jul-22-22Downgrade Jefferies Buy → Hold
May-20-21Initiated Robert W. Baird Outperform $9
Feb-18-21Initiated Jefferies Buy $6
Jan-04-21Upgrade William Blair Mkt Perform → Outperform
Jun-27-18Initiated Maxim Group Buy $6
Feb-08-18Reiterated Chardan Capital Markets Buy $30 → $22
Jun-12-24 08:02AM
Jun-11-24 04:20PM
Jun-07-24 08:30AM
May-29-24 08:30AM
08:30AM Loading…
May-23-24 08:30AM
May-14-24 06:59AM
May-13-24 10:00AM
May-07-24 08:30AM
Apr-25-24 08:30AM
Apr-19-24 07:13AM
Apr-09-24 01:28PM
Apr-01-24 08:30AM
Mar-31-24 10:00AM
06:24AM Loading…
Mar-26-24 06:24AM
Mar-11-24 08:30AM
Feb-28-24 08:30AM
Feb-21-24 09:55AM
Feb-19-24 12:24PM
Feb-15-24 08:20AM
Feb-14-24 03:45PM
Feb-13-24 04:59PM
Feb-07-24 07:38AM
Feb-06-24 08:30AM
Jan-26-24 09:04AM
Dec-29-23 08:40AM
Dec-27-23 08:30AM
Dec-20-23 02:15PM
01:03PM Loading…
Nov-11-23 01:03PM
Nov-09-23 04:30PM
Nov-08-23 08:30AM
Nov-07-23 08:30AM
Nov-06-23 08:00AM
Oct-05-23 08:30AM
Oct-02-23 07:30AM
Sep-21-23 04:43PM
Sep-12-23 08:30AM
Sep-05-23 09:00AM
Aug-22-23 08:30AM
Aug-15-23 07:37AM
Aug-11-23 10:34AM
Aug-10-23 04:21PM
Aug-08-23 04:30PM
Aug-07-23 05:46PM
Jul-17-23 08:00AM
Jul-13-23 04:05PM
Jun-28-23 04:25PM
Jun-27-23 04:30PM
Jun-23-23 08:30AM
Jun-21-23 08:30AM
Jun-16-23 12:36PM
Jun-13-23 08:00AM
Jun-07-23 09:00AM
Jun-06-23 04:30PM
Jun-01-23 08:30AM
May-30-23 04:15PM
May-24-23 08:30AM
Apr-19-23 08:30AM
Apr-06-23 08:30AM
Mar-30-23 03:18PM
Mar-22-23 08:30AM
Mar-08-23 08:30AM
Mar-02-23 08:30AM
Mar-01-23 08:30AM
Feb-08-23 12:49PM
Feb-07-23 06:15PM
Feb-06-23 09:09AM
Feb-02-23 09:00AM
Jan-24-23 08:30AM
Jan-19-23 08:30AM
Jan-10-23 08:30AM
Dec-30-22 08:30AM
Dec-21-22 10:56AM
Dec-16-22 08:35AM
Dec-13-22 08:35AM
Dec-06-22 08:30AM
Nov-30-22 08:30AM
Nov-17-22 08:30AM
Nov-15-22 12:00PM
Nov-10-22 06:45PM
Nov-04-22 08:30AM
Nov-03-22 08:30AM
Oct-26-22 09:00AM
Oct-22-22 08:02AM
Oct-19-22 04:30PM
Oct-06-22 08:30AM
Oct-03-22 08:30AM
Sep-24-22 08:10AM
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COMMODORE CAPITAL LP10% OwnerAug 07 '23Buy23.15775,75617,961,0791,575,000Aug 09 04:10 PM